Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr — APBI RISE  

Breast Cancer Clinical Trial

Official title: SH APBI RISE: Evaluating the Safety and Efficacy of a Novel IMRT/VMAT-based Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr

Status Recruiting

Clinical Trial Summary

This study will use an adjuvant radiation therapy regimen called APBI (accelerated partial breast irradiation). APBI is a treatment option available to women considered to have an early stage, low-risk breast cancer. The standard external beam-based APBI treatment delivers treatments every other day for five treatments, over ten calendar days. The APBI in this study is modified and will deliver five once daily treatments over consecutive treatment days, with a slightly lower dose of radiation each day as compared to the standard external beam-based APBI treatment.

Clinical Trial Description

This is a prospective interventional cohort study in breast cancer participants. The purpose of this study is to track physician-assessed cosmetic outcomes as the primary study endpoint, and compare these results to historical trials in which women with favorable risk early stage breast cancer underwent a course of adjuvant WBI. ;

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

• NCT number: NCT05591547
• Study type: Interventional
• Source: Sanford Health
• Contact: Ryan Nowak, MD
• Phone: 605-328-6000
• Email: Ryan.Nowak@sanfordhealth.org
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2022
• Completion date: March 31, 2027